- Home
- GDHG vs BCDA Comparison
GDHG vs BCDA Comparison
Compare GDHG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDHG
- BCDA
- Stock Information
- Founded
- GDHG 2008
- BCDA N/A
- Country
- GDHG China
- BCDA United States
- Employees
- GDHG N/A
- BCDA N/A
- Industry
- GDHG Services-Misc. Amusement & Recreation
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- GDHG Consumer Discretionary
- BCDA Health Care
- Exchange
- GDHG Nasdaq
- BCDA Nasdaq
- Market Cap
- GDHG 23.6M
- BCDA 7.9M
- IPO Year
- GDHG 2023
- BCDA N/A
- Fundamental
- Price
- GDHG $2.53
- BCDA $2.68
- Analyst Decision
- GDHG
- BCDA Strong Buy
- Analyst Count
- GDHG 0
- BCDA 1
- Target Price
- GDHG N/A
- BCDA $25.00
- AVG Volume (30 Days)
- GDHG 212.9K
- BCDA 73.1K
- Earning Date
- GDHG 07-30-2024
- BCDA 11-06-2024
- Dividend Yield
- GDHG N/A
- BCDA N/A
- EPS Growth
- GDHG N/A
- BCDA N/A
- EPS
- GDHG 1.62
- BCDA N/A
- Revenue
- GDHG $25,549,903.00
- BCDA $428,000.00
- Revenue This Year
- GDHG N/A
- BCDA $6.92
- Revenue Next Year
- GDHG N/A
- BCDA N/A
- P/E Ratio
- GDHG $1.61
- BCDA N/A
- Revenue Growth
- GDHG N/A
- BCDA 0.71
- 52 Week Low
- GDHG $1.90
- BCDA $1.96
- 52 Week High
- GDHG $1,249.50
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- GDHG 33.93
- BCDA 49.01
- Support Level
- GDHG $2.23
- BCDA $2.39
- Resistance Level
- GDHG $2.90
- BCDA $2.90
- Average True Range (ATR)
- GDHG 0.31
- BCDA 0.18
- MACD
- GDHG 0.14
- BCDA -0.00
- Stochastic Oscillator
- GDHG 62.50
- BCDA 53.70
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).